The stock of Medpace Holdings Inc (NASDAQ:MEDP) reached all time high today, Nov, 14 and still has $54.49 target or 57.00% above today’s $34.71 share price. This indicates more upside for the $1.41B company. This technical setup was reported by Barchart.com. If the $54.49 PT is reached, the company will be worth $803.70 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 110,287 shares traded hands. Medpace Holdings Inc (NASDAQ:MEDP) has risen 6.00% since October 15, 2016 and is uptrending. It has outperformed by 1.02% the S&P500.
Medpace Holdings Inc (NASDAQ:MEDP) Ratings Coverage
Out of 5 analysts covering Medpace Holdings Inc. – Common Stock (NASDAQ:MEDP), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. Medpace Holdings Inc. – Common Stock has been the topic of 5 analyst reports since September 6, 2016 according to StockzIntelligence Inc. The company was initiated on Tuesday, September 6 by UBS. On Tuesday, September 6 the stock rating was initiated by Wells Fargo with “Outperform”. Credit Suisse initiated the shares of MEDP in a report on Tuesday, September 6 with “Outperform” rating. The stock has “Neutral” rating given by Robert W. Baird on Tuesday, September 6. The stock has “Hold” rating given by Jefferies on Tuesday, September 6.
According to Zacks Investment Research, “Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio.”
More notable recent Medpace Holdings Inc (NASDAQ:MEDP) news were published by: Businesswire.com which released: “Medpace Holdings, Inc. Reports Third Quarter 2016 Results” on November 03, 2016, also Businesswire.com with their article: “Medpace Holdings, Inc. Announces Pricing of Initial Public Offering” published on August 10, 2016, Businesswire.com published: “Medpace Holdings, Inc. to Present at Two Upcoming Investor Conferences” on August 17, 2016. More interesting news about Medpace Holdings Inc (NASDAQ:MEDP) were released by: Moodys.com and their article: “Moody’s upgrades Medpace to B1; outlook stable” published on August 25, 2016 as well as Seekingalpha.com‘s news article titled: “IPO Quiet Period Expiration: Medpace Holdings, Inc.” with publication date: August 30, 2016.
MEDP Company Profile
Medpace Holdings, Inc. is a holding company. The Firm operates as a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Firm is focused on conducting clinical trials across therapeutic areas, with focus in cardiology, metabolic disease, oncology, endocrinology, central nervous system (CNS), and Anti-Viral and Anti-Infective (AVAI). The Firm provides a suite of services supporting the entire clinical development process from Phase I to Phase IV. It offers these services across a range of therapeutic areas. The Company’s suite of clinical development services includes Medical Affairs, Clinical Trial Management, Study Feasibility, Study Start-Up, Clinical Monitoring, Global Regulatory Affairs, Medical Writing, Biometrics, Pharmacovigilance, Core Laboratory, Quality Assurance, Laboratories, Clinics and Customers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.